EAM Investors LLC Acquires Shares of 63,078 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)

EAM Investors LLC purchased a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 63,078 shares of the company's stock, valued at approximately $3,531,000. EAM Investors LLC owned approximately 0.10% of Rhythm Pharmaceuticals at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Barclays PLC boosted its position in shares of Rhythm Pharmaceuticals by 79.6% in the 3rd quarter. Barclays PLC now owns 106,397 shares of the company's stock worth $5,574,000 after purchasing an additional 47,166 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Rhythm Pharmaceuticals by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,256,188 shares of the company's stock valued at $65,824,000 after purchasing an additional 3,499 shares during the period. Franklin Resources Inc. lifted its stake in Rhythm Pharmaceuticals by 11.5% in the 3rd quarter. Franklin Resources Inc. now owns 259,416 shares of the company's stock valued at $13,033,000 after acquiring an additional 26,739 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Rhythm Pharmaceuticals by 241.9% during the third quarter. Principal Financial Group Inc. now owns 32,586 shares of the company's stock worth $1,707,000 after purchasing an additional 23,054 shares during the last quarter. Finally, Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals in the 4th quarter valued at about $28,000.

Insider Buying and Selling

In related news, insider Pamela J. Cramer sold 20,760 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Tuesday, April 8th. The stock was sold at an average price of $60.14, for a total transaction of $1,248,506.40. Following the sale, the insider now owns 19,209 shares of the company's stock, valued at approximately $1,155,229.26. This trade represents a 51.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Yann Mazabraud sold 75,000 shares of the business's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the transaction, the executive vice president now directly owns 40,370 shares in the company, valued at $2,078,247.60. This trade represents a 65.01 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 146,641 shares of company stock valued at $8,112,177. 5.60% of the stock is owned by company insiders.

Rhythm Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ RYTM traded up $0.51 during trading on Monday, reaching $62.25. The company had a trading volume of 126,843 shares, compared to its average volume of 541,027. The stock has a market cap of $3.94 billion, a PE ratio of -14.38 and a beta of 2.32. The business's 50-day moving average is $54.79 and its 200 day moving average is $55.73. Rhythm Pharmaceuticals, Inc. has a 12-month low of $35.17 and a 12-month high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million. On average, analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on RYTM shares. Canaccord Genuity Group upped their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. JMP Securities reiterated a "market outperform" rating and set a $75.00 price target on shares of Rhythm Pharmaceuticals in a report on Monday, December 23rd. Jefferies Financial Group started coverage on Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a "buy" rating and a $80.00 price objective on the stock. Finally, Stifel Nicolaus started coverage on shares of Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They issued a "buy" rating and a $78.00 target price for the company. Thirteen analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $74.92.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.